Isogenica successfully hit milestones in relation to collaboration announced in 2010
February 25 2011 Isogenica Ltd (Cambridge, UK) and Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian drug discovery company, today announced the successful outcome of their proof-of-concept project to demonstrate the compatibility of Isogenica’s proprietary CIS display technology with Phylogica’s Phylomer drug discovery platform.
Isogenica has been successful in hitting the milestones related to the collaboration announced in January 2010. The objectives of the project were to use Isogenica’s CIS display to achieve further optimisation of Phylogica’s lead compounds targeting CD40 ligand (CD40L).
The positive outcome of this project demonstrates that Isogenica’s CIS display is highly compatible with Phylogica’s Phylomer libraries and can be used to screen trillions of variants of Phylomers in a significantly shorter timeframe than is currently achievable. The validated combination of technologies offers a powerful extension of Phylogica’s drug discovery platform and could open up new partnership opportunities with the pharmaceutical industry. The two companies are now exploring a broader alliance to commercialise the combined potential of their technologies.
Isogenica’s CEO, Kevin Matthews, said:
“The pharmaceutical industry is constantly exploring new molecular structures that could lead to significant new medical treatments. The structural diversity of Phylogica’s Phylomer libraries, as a starting point, combined with the ability to rapidly generate trillions of Phylomer mutations, fast tracks evolution and could lead to improved lead candidates in a significantly shorter time frame.”
Dr Paul Watt, Phylogica’s CEO, said: “We are excited by the success of this project with Isogenica. We believe that the use of CIS display will accelerate the rapid scaling of Phylogica’s screening capability to meet increased demand from our prospective pharmaceutical partners. Phylomers are sourced from the most structurally diverse peptide libraries in the world. The primary screening of Phylomer libraries using CIS display could increase this diversity, resulting in even higher quality outputs. Moreover, the elimination of several time-consuming screening steps requiring living micro-organisms has major scaling advantages, including the ability to screen against dozens of disease targets in parallel.”
Dr Watt added: “This combined capability could stimulate significant new revenue opportunities for our collaborative drug discovery services business. Likewise, these new capabilities could benefit our existing alliances and we’re currently reviewing how they may be applied.”
For further information, please contact:
Kevin Matthews, CEO, Isogenica
T: +44 (0)1799 533682
Isogenica specialises in the discovery and optimisation of therapeutic and diagnostic peptides, proteins and antibodies using its proprietary technology, CIS display. Founded in 2000 Isogenica has developed a unique capability in the field of protein engineering. Isogenica’s CIS display technology is an in vitro display technology that allows the rapid generation of polypeptide and antibody libraries from which it is possible to select lead molecules with high affinity and specificity for most targets. www.isogenica.breathetechnology.com
Phylogica Limited (ASX: PYC) is biotechnology company based in Perth, Australia and Oxford UK, with a world-class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics. The Company was incorporated in 2001 as a spin out from the Telethon Institute for Child Health Research (Perth, Australia) and the Fox Chase Cancer Center (Philadelphia, USA). Phylogica’s strategy is to accelerate cash sustainability by focusing on collaborative drug discovery partnerships. The Company’s Phylomer® libraries have been optimised by natural evolutionary selection for peptides with stable drug-like structures. The unique qualities of Phylogica’s Phylomer libraries are validated by its partnerships with Roche, MedImmune (the worldwide biologics unit of AstraZeneca) and Pfizer. www.phylogica.com
About Phylomer® Peptides
Phylomer peptides are derived from biodiverse natural sequences, which have been selected by evolution to form stable structures, which can bind tightly, and specifically to disease associated target proteins, both inside and outside cells. Suitable targets for blockade by Phylomers include protein interactions that promote multiple diseases, such as infectious diseases, cancer, autoimmunity, and heart disease. Phylomer peptides can have drug-like properties, including specificity, potency and thermal stability, and are capable of being produced by synthetic or recombinant manufacturing processes. Phylomer peptides are also readily formulated for administration by a number of means, including parenteral or intranasal delivery approaches.